China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)

China · Delayed Price · Currency is CNY

16.07

-0.03 (-0.19%)

Nov 6, 2026, 3:00 PM CST

Market Cap	16.60B -16.5%
Revenue (ttm)	10.66B -2.8%
Net Income	1.56B -1.3%
EPS	1.50 -1.4%
Shares Out	1.03B
PE Ratio	10.69
Forward PE	9.89
Dividend	0.48 (2.98%)
Ex-Dividend Date	Jul 28, 2026

Volume	4,640,216
Open	15.85
Previous Close	16.10
Day's Range	15.85 - 16.17
52-Week Range	15.03 - 19.77
Beta	-0.01
Analysts	Strong Buy
Price Target	23.54 (+46.48%)
Earnings Date	Oct 28, 2026

About SHA:600062

China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People’s Republic of China. The company offers pharmaceutical products for blood pressure and sugar, injections, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, inflammation, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 and is headquartered in Beijing, the People’s Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a subsidiar... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1939

Employees 13,184

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 600062

Full Company Profile

Financial Performance

In 2025, SHA:600062's revenue was 11.00 billion, a decrease of -1.88% compared to the previous year's 11.21 billion. Earnings were 1.65 billion, an increase of 1.18%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 600062 stock is "Strong Buy." The 12-month stock price target is ¥23.54, which is an increase of 46.48% from the latest price.

Price Target

¥23.54

(46.48% upside)

Analyst Consensus: Strong Buy

Stock Forecasts